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quently with transcatheter techniques than with
surgery.8 On the other hand, surgery results in a signif-
icant morbidity.9 However, no formal comparison has
been reported concerning results, closure rates, morbid-
ity, and complications of transcatheter and surgical clo-
sure of ASDs performed at the same time and in the
same institution. The purpose of our study was to com-
pare results and complications of both treatment modal-
ities in patients with a defect in the oval fossa (ostium
secundum ASD) with a pulmonary/systemic flow ratio
(Qp/Qs) of 1.5:1 or larger who were treated during a 1-
year period. 
Methods
Patient selection. This study comprised all consecutive
patients referred to our hospital during the 1-year period start-
ing on May 7, 1997 (the day of the first implantation of an
Amplatzer septal occluder device [AGA Medical
Corporation, Golden Valley, Minn] in our institution), with an
C ardiac surgery for closure of atrial septal defects(ASDs) has been practiced for more than 45 years
and is the method of choice in most centers in which
patients with ASDs are treated. Recently, a variety of
devices for transcatheter closure of ASDs have become
available1-6 and an increasing number of patients are
treated with this alternative to surgery.7
Complete closure of ASDs has been achieved less fre-
Objectives: Results and complications of surgical versus transcatheter
treatment of atrial septal defect in the current era are compared.
Methods: All consecutive patients with a secundum atrial septal defect
and a pulmonary/systemic flow ratio of 1.5:1 or more who presented
between May 1997 and June 1998 were enrolled in this study. All
patients except those who initially had defects not feasible for interven-
tional occlusion were catheterized to allow interventional closure of the
defects. All patients in whom interventional closure could not be per-
formed underwent surgical closure. Results: Sixty-one patients under-
went surgery at a median age of 20 years (0.5-74 years) and 61 had the
defect closed with an Amplatzer device (AGA Medical Corporation,
Golden Valley, Minn) at a median age of 12 years (0.8-77.7 years) (P >
.2). Hospital stay in surgically treated patients was 8 days (6-19 days)
versus 3 days (3-14 days) in interventionally treated patients (P < .001).
Atrial septal defect and shunt sizes were larger in the surgical group (P
< .001). Closure rates in the 2 groups were identical (98%). One patient
(68 years) in the surgical group had a perforated duodenal ulcer that
necessitated an operation 8 days after closure of the atrial septal defect,
and 1 (26 years) had an infected lateral thoracotomy wound necessitat-
ing plastic surgery. Embolization of the Amplatzer device to the left ven-
tricle was observed in 1 patient (29 years). The device could be retrieved
from the heart, but vascular surgery was required to extract it from the
femoral artery. Conclusions: As complete closure rates and complications
are identical, but duration of hospital stay is shorter with less morbidi-
ty, we prefer implantation of an Amplatzer septal occluder to surgery
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isolated ASD located in the oval fossa (so-called secundum
ASD) and a left-to-right shunt with a Qp/Qs of 1.5:1 or larg-
er. Patients with associated partial anomalous pulmonary
venous drainage or atrioventricular valve abnormalities were
excluded. We also excluded patients with patent foramen
ovale associated with a history of stroke or transient ischemic
attacks, a small ASD with a left-to-right shunt (Qp/Qs) of less
than 1.5:1, or a residual ASD after a previous operation.
The following patients were referred immediately to the
surgeon without cardiac catheterization: (1) those in whom
echocardiography revealed a single defect too large for occlu-
sion, multiple defects unsuitable for interventional closure, or
a defect too close to the superior vena cava, pulmonary veins,
coronary sinus, or atrioventricular valves (predictable failure
of interventional closure) and (2) those patients who objected
to closure by a device (missing consent declaration). All oth-
ers underwent cardiac catheterization with angiography and
balloon sizing of the ASD so that interventional occlusion
could be performed.
At cardiac catheterization, standard fluid-filled catheters
were used and the Qp/Qs flow ratio was measured by oxime-
try by means of the Fick principle. The size of the ASD was
determined with balloon catheters. To determine the size of
the ASD, we used the size of the balloon deformed by the
ASD monitored by transesophageal echocardiography as it
was pulled through the ASD in all 108 patients who went to
the catheterization laboratory. The largest balloon that could
be pulled through the defect was considered to represent the
balloon-stretched size of the ASD.10 In the remaining 14
patients, who did not undergo cardiac catheterization, the size
of the ASD was measured only by transesophageal echocar-
diography before the operation, but without balloon sizing. 
All patients gave written informed consent to Amplatzer
device closure, and the implantation protocol had been
approved by the local institutional review board. The techni-
cal details of the implantation of the Amplatzer device have
been described elsewhere.6,7,11 A 7F or 8F long sheath was
used to deliver the Amplatzer device. Transesophageal
echocardiography with a multiplane transesophageal probe
interfaced with a Vingmed 800 (Vingmed Sound, Horten,
Norway) sector scanner or a monoplane probe interfaced
with a Siemens Sonoline 1200 (Siemens, Erlangen,
Germany) sector scanner to monitor device placement was
performed in all. The following patients were referred to the
surgeon: patients with a single ASD and a balloon-stretched
ASD diameter of more than 26 mm, those with multiple
ASDs, and those with a distance of less than 5 mm between
the margins of the ASD and the mitral or tricuspid valves,
superior vena cava, right upper pulmonary vein, and coronary
sinus. All patients were sedated with intravenous midazolam
in a dose of 0.1 to 0.2 mg/kg 30 minutes before entering the
catheterization laboratory. This dose was followed by a con-
tinuous infusion of propofol (3-5 mg/kg per hour) during the
procedure. Neither endotracheal intubation nor mechanical
ventilation was required in any patient. 
Patients who underwent surgery were operated on under
general anesthesia with the aid of cardiopulmonary bypass.
The right atrium was opened after a median thoracotomy. The
ASD was closed either by direct suture (n = 9) or by a peri-
cardial patch (n = 52). In 13 (41%) of 29 female patients older
than 12 years, a lateral thoracotomy was used. Before hospital
discharge all patients underwent complete physical examina-
tion, color Doppler echocardiographic study, and chest radi-
ography. In the patients with Amplatzer occluder treatment,
chest radiography was repeated at the 3-month follow-up visit.
A residual ASD was considered to be present if color Doppler
flow mapping performed on the day of hospital discharge
revealed a left-to-right shunt across the atrial septum. 
Table I. Clinical data of 122 patients with ASD treated with implantation of Amplatzer device or surgery
Amplatzer (n = 61) Surgery (n = 61)
Median Quartile Median Quartile median 95% CI around 
(range) (25%/75%) (range) (25/75%) P value difference median difference
Age (y) 12 (0.8-77.7) 4.4/35.6 20 (0.5-74.0) 5.5/45.0 >.2 8 –7 to 23.4
Follow-up 7 (1-13) 3/10 8 (2-13) 5/11 .19 1 –0.947 to 4.053
(mo)
Qp/Qs 1.8 (1.5-3.7) 1.6/2.0 2.4 (1.5-4.0) 1.8/2.9 <.001 0.6 0.194 to 0.794
ASD size 14 (7-26) 11/20 20 (9-40) (n = 47) 16/30 <.001 6 2.7 to 10.3
(mm)
Length of 3 (3-14) 3/3 8 (6-19) 7/10 <.001 5 4.745 to 5.745
hospital stay (d)
Size of Amplatzer 13 (7-26) 11/20
device (mm)
Fluoroscopy time (min) 7.3 (0-20.3) 5.9/10.4
Procedure time (min) 110 (50-180) 90/135
Aortic crossclamp time 16 (8-21) 11/17
(min)
Bypass time (min) 33 (22-45) 26/38
ASD, Atrial septal defect; CI, confidence interval; diff, difference; QpQs, pulmonary/systemic flow ratio.
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Statistical analysis. Results are expressed as median,
range, and 25% and 75% quartiles, respectively. Also, the dif-
ferences between the medians have been calculated, as has an
estimate of the 95% confidence interval around that differ-
ence. A bootstrap method was used to calculate that 95% con-
fidence interval.12 The Mann-Whitney U test was used to
compare the group treated by surgery with the one treated by
catheter intervention. Only ASDs that had been measured by
balloon sizing were compared between the 2 groups. To
prove both methods, the 95% confidence interval for a differ-
ence of event rates was calculated by means of the Fleiss for-
mula.13 The surgical and interventional methods showed
equivalent success with respect to frequency of atrial arrhyth-
mias and evidence of residual shunt if the 95% confidence
interval lies between –0.1 and 0.1.14
Results
Among the 122 unselected consecutive patients with
an ASD, 14 were primarily referred to the surgeon
without cardiac catheterization (1) because of the pre-
dictable failure of interventional closure (large single
ASD or multiple ASDs unsuitable for interventional
closure by echocardiography, n = 8; ASD close to the
superior vena cava, n = 2) or (2) because the patient did
not consent to interventional closure (n = 4). The other
108 patients were sent to the catheterization laboratory
with the intention to treat the ASD by device closure. In
61 patients device closure was successful, and in 47
device closure was impossible because of the large size
of the defect (n = 28), multiple defects (n = 8), or loca-
tion of the defect too close to the inferior vena cava (n
= 5), too close to the superior vena cava (n = 2), too
close to the coronary sinus (n = 2), or too close to the
atrioventricular valves (n = 2). 
Patients’ data are summarized in Table I. Median age
at intervention in the 61 patients undergoing Amplatzer
device closure was 12 years (0.8–77.7 years), with 19
patients being older than 18 years, whereas in the
patients undergoing surgery the median age was 20
years (0.5–74.0 years), with 34 patients being in the
adult age group (P > .2). Duration of follow-up in the
group treated by surgery was 8 months (2-13 months)
and in the group treated by intervention, 7 months (1-
13 months) (P = .19). The 5 patients who were treated
by either method in the first 2 years of life had symp-
toms consisting of failure to thrive, frequent chest
infections, or both. The patients who underwent
surgery had a larger ASD with a larger shunt than those
who had an Amplatzer device implanted (Table I). In
the surgical group, shunt size could be calculated in
only 47 of the 61 patients who underwent cardiac
catheterization; the other 14 patients were not catheter-
ized before the operation. Complete closure of the ASD
was achieved in 98% of patients with both methods
(Table I).
Two patients, 1 in each group, had a trivial residual
ASD, smaller than 3 mm in diameter, assessed by
cross-sectional transesophageal echocardiography.
Complications of surgery and Amplatzer implanta-
tion were rare and are summarized in Table II. Only
those atrial arrhythmias that occurred de novo from
sinus rhythm before closure were considered a compli-
cation of treatment. The 10 patients with arrhythmias
were successfully treated by cardioversion (n = 4) or
administration of verapamil (n = 2) and sotalol (n = 2).
Two patients have persistent atrial fibrillation and are
receiving warfarin sodium.
There were no vascular complications in the patients
treated by catheter intervention except in 1 patient,
aged 29 years, in whom embolization of a 15-mm
Amplatzer device into the left ventricular outflow tract
occurred about 6 hours after implantation and resulted
in monomorphic premature ventricular beats (about 10-
15 beats/min). The device could be retrieved by trans-
catheter technique into the left femoral artery but could
Table II. Complications and age at time of treatment in 122 patients with ASD who underwent closure by surgery
or intervention
Patients treated by Patients treated with 95% CI of 
surgery (n = 61) Amplatzer device (n = 61) event rate difference
Atrial flutter n = 5 (44 ±7 y) n = 2 (54 and 77 y) –0.13; 0.03
Atrial fibrillation n = 2 (68 and 74 y) 0 –0.08; 0.012
Residual shunt >48 h n = 1 (20 y) n = 1 (28 y) –0.045; 0.045
Intermittent SVT n = 1 (32 y) –0.013; 0.042
Pericardial effusion n = 2 (13 and 20 y)
Wound infection n = 1 (26 y)
Perforation of duodenal ulcer n = 1 (68 y)
Embolism of Amplatzer device n = 1 (29 y)
ASD, Atrial septal defect; CI, confidence interval; SVT, supraventricular tachycardia.
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not be pulled out of the vessel, so that vascular surgery
was required. This patient subsequently underwent sur-
gical closure of the ASD. In the patients treated surgi-
cally, 1 serious wound infection of a lateral thoracoto-
my scar led to secondary healing and subsequent
plastic surgery. On the 8th postoperative day, after
uneventful recovery and after having received the anti-
histamine ranitidine for 3 days, 1 patient began having
acute abdominal pain, vomiting, and fever. An abdom-
inal operation revealed a perforated duodenal ulcer.
There were no deaths within 30 days after either the
surgical or transcatheter method of ASD occlusion.
Blood products were needed only in the patients under-
going surgery: 9 of 61 received an autotransfusion of
their own previously donated blood, and 3 of 61 (5%)
received donor blood. 
Discussion
Our data show that 50% of unselected secundum
ASDs with a minimum Qp/Qs ratio of 1.5:1 can be suc-
cessfully treated by Amplatzer device implantation in
patients ranging from infancy to more than 70 years
old. The closure rate is identical for the 2 methods, and
the residual ASDs were trivial and of no hemodynamic
significance. As the closure rate with the new
Amplatzer device is identical to that of surgery, com-
parison of the 2 methods should focus on morbidity.
Prevalence of serious complications was identical, but
absence of the need for blood products, morbidity, and
length of hospital stay are in favor of Amplatzer device
closure.
Complications of surgery. Mortality and morbidity
of surgical closure of ASDs in the current era has
recently been reported in detail.9 As in our series,
incomplete closure of the ASD after surgery is rare.9
Mortality and serious morbidity are also rarely seen.9
In the present series, surgical complications (Table II)
occurred because of attempted minimally invasive
repair with a lateral thoracotomy.15 The exacerbation of
a duodenal ulcer under stress in the hospital, however,
could have happened without regard to the type of ASD
closure. A minor but frequently observed morbidity is
associated with the postpericardiotomy syndrome,16
which did not lead to pericardial tamponade or the need
for pericardiocentesis in our series. The occurrence of
atrial flutter/fibrillation after closure of an intra-atrial
communication was slightly more frequent in patients
treated surgically (Table II), is known to increase with
age,17 as in the present series, and is probably related to
the pre-treatment distention of the right atrium.18
Morbidity unique to surgical therapy is related to the
possible risks of blood transfusions, which were not
required in patients undergoing Amplatzer device clo-
sure. Morbidity related to endotracheal intubation and
general anesthesia required for surgery was not appar-
ent in our patient group but is a potential hazard.
Complications of nonoperative closure. Real and
potential problems with device closure of ASDs have
been reported, including early death after the procedure,
possibly related to dislodgment of an iliac vein throm-
bus while the sheath was being advanced,1 late device
dislocation with left atrial thrombus formation and sys-
temic embolism,19 failure to retrieve a misplaced device
necessitating surgery,20 and incomplete closure of the
ASD.1,2,3,7,11 The fact that previous experience with
smaller patient numbers treated with the novel
Amplatzer device7,6,11 did not include device emboliza-
tion illustrates the need for multicenter studies in a large
number of patients. The complication could not be
attributed to our learning curve, because it occurred late
in our experience after implantation of more than 100
Amplatzer devices. Embolization has previously been
reported with the use of other devices21 and, as in our
case, was not associated with particularly large defects.
Retrospectively, we assume that the rim of the ASD was
too floppy to secure the device.
Incomplete closure can occur with the use of differ-
ent devices,1,2,8 and its incidence may not be different
with the Amplatzer septal occluder.6,7,11 This study,
however, demonstrated a closure rate identical to that
of surgery. One of the potential advantages of the
Amplatzer septal occluder is the previously reported
retrievability.6,11 Although retrieval was necessary in 1
patient, we were able to extract the embolized device
from the left ventricle without damage to the cardiac
valves; vascular surgery was necessary to retrieve it
from the peripheral vessel. 
Compared with published reports on alternative
devices,2,5,21 the fluoroscopy time needed to implant
the Amplatzer device appears to be short6 (Table I).
This time can be reduced further if more Amplatzer
devices will be implanted with echocardiographic
guidance alone without the need for fluoroscopy, com-
pletely avoiding any potential morbidity to the patient
or operator from irradiation.22
In the future it may become possible to close multi-
ple defects and those with a diameter larger than 26
mm.23
Limitations of this study. We could not perform a
randomized study designing patients to a particular
treatment protocol, because the patients treated with
surgery had larger defects, multiple defects, or defects
too close to the atrioventricular valves, coronary sinus,
and superior or inferior venae cavae. Second, access to
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the heart in the surgically treated patients was achieved
in a different manner depending on age and sex of the
individual patient and the individual surgeon’s prefer-
ence. Third, the difference in shunt size may have influ-
enced the incidence of postoperative atrial flutter/fibril-
lation. Fourth, the length of hospital stay after closure
may vary from country to country, so that our result of
a significant difference in length of hospital stay after
surgery cannot necessarily be extrapolated to the med-
ical systems of other countries. 
This is a nonrandomized study with evidence of sig-
nificant patient selection bias, which limits the possi-
bility of comparing the 2 strategies and may influence
our conclusions.
Conclusions
Despite the described limitations of this study, we
conclude that Amplatzer device closure of ASDs is
preferable to surgical closure whenever the anatomy of
the ASD is suitable; closure rates of nonoperative ASD
occlusion are identical to those of surgical closure, and
complications with the 2 methods are comparable. We
believe that transcatheter closure of ASDs with the
Amplatzer septal occluder is a definite alternative to
surgery in an increasing number of selected patients.
We thank Dr Ulrich Mansmann of the Institute of Medical
Statistics Epidemiology and Informatics at the Free
University of Berlin for assistance with the statistical evalua-
tion of the paper and Silke Uhlmann for aid in finishing the
manuscript.
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Commentary
Interventional catheter device closure of secundum
atrial septal defects (ASDs) has become consistently
feasible in recent years. Although it is logical that this
technique might offer advantages over surgical closure,
no real comparison of the 2 methods has been previ-
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ously reported. As current catheter devices were being
developed and refined, traditional surgical approaches
were also being altered by the development of less
invasive techniques such as partial sternotomies and
much smaller skin incisions. Berger and colleagues
have evaluated a consecutive series of 102 patients who
underwent ASD closure with surgery (n = 61) or an
Amplatzer device (n = 61) during a 1-year interval
beginning May 1997. Their series begins with the first
patient to undergo device closure in their institution.
Although this evaluation was prospective, the patients
were not randomized. The patients undergoing surgery
were older and had larger defects and larger shunts. In
fact, the surgical series essentially consisted of those
patients in whom device closure was not possible. In
addition, the median age of the patients in both groups
was much older than that of the usual patient currently
undergoing ASD closure. The ASD closure rate was
98% in each group, and there were no deaths. Two
patients undergoing surgical treatment had significant
complications, and in 1 patient the Amplatzer device
embolized, requiring surgical retrieval. Length of stay
was shorter in the patients receiving the Amplatzer
device (3 days) than in those treated surgically (8 days).
On the basis of the similar outcomes, the absence of
need for blood products, and the decreased length of
stay, the authors conclude that the Amplatzer device is
preferable to surgical closure of ASDs.
Despite the fact that the series are concurrent and
from the same institution, the report is flawed by the
fact that the 2 groups are not comparable, as is pointed
out by the authors. True randomization into compara-
ble series could have been achieved by including only
those patients who were suitable for either surgical or
device closure, and the results would have been more
meaningful. Most patients undergoing surgical closure
of ASD now are discharged in 3 days or less, and it is
unfair to use decreased length of stay in this series as a
reason for the superiority of the Amplatzer device.
However, in our institution, as noted below, most
patients receiving the device are discharged in 24
hours. The authors have fairly presented one of the
major complications of device closure, that is, emboli-
zation. Although uncommon, it is potentially the cause
of a very unsatisfactory outcome (stroke or death) in a
patient with a relatively benign defect. Despite these
criticisms, the authors have indeed demonstrated the
ability to successfully close secundum ASDs in about
half of the patients with this problem.
At the Medical University of South Carolina over the
past 23 months, 60 patients (aged 2-75 years) have under-
gone successful device closure of ASDs, and 97% were
discharged in less than 24 hours (W. Radtke, personal
communication). No significant complications have
occurred. During the same interval, 16 patients were eval-
uated by echocardiography (without the need for
catheterization, as in the series reported by Berger and
associates) and were believed to be unsuitable for device
closure. Because catheter device closure is much less
invasive, this approach probably will become increasing-
ly popular with pediatric cardiologists, patients, and fam-
ilies. With further experience and device evolution, this
technique will become applicable in a larger proportion
of patients with these defects than the 50% reported here.
It is likely, however, that a significant subset will contin-
ue to have defects unsuitable for device closure; thus sur-
gical intervention will still be required in that group.
Surgical closure should continue to provide excellent
results as in the past, but less invasive techniques offer the
possibility of decreasing morbidity.




It has been more than 20 years since the first report
of successful transcatheter device closure of atrial sep-
tal defects (ASDs).1 In the past decade, at least 6 dif-
ferent devices have been in widespread clinical trials;
several are now approved for use in many countries.
Past reports have compared catheter closure of ASDs
with historical surgical series. Berger and associates
are to be commended, because theirs is the first study
in which an attempt has been made to compare concur-
rent results of surgical and device closure of ASDs.
Surgery and device closure were each performed on 61
patients. Complications and efficacy of the 2 proce-
dures were similar at hospital discharge except for a
higher incidence of postprocedure atrial arrhythmias in
the surgical group.
The limitations of this study highlight the difficulties
in performing such a comparison at 1 center. The sur-
gical group was composed entirely of patients who
were deemed inappropriate for the Amplatzer device,
in most cases because their ASDs were too large or had
an inadequate rim of septum to secure the device. Over
two thirds of the patients who ultimately underwent
surgical closure had previously gone to the catheteriza-
tion laboratory with the intent of device closure. Not
surprisingly, patients who underwent surgery were
older, had larger defects, and had bigger shunts than
those who underwent device closure. The differences
between the 2 treatment groups are of more than acad-
emic importance. As the authors note, they may be
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implicated as a cause for the higher incidence of atrial
flutter and fibrillation after surgery. Even accepting the
fact that there were major differences in patient popu-
lation between the arms of this study, it seems very
unlikely that surgery in a comparable group would
have been associated with significantly fewer compli-
cations than device closure.
Although the limited follow-up of most reports may
make it a bit overly enthusiastic to conclude that device
closure is now the preferred method of ASD repair, it is
reasonable and appropriate to conclude that device clo-
sure is a viable and acceptable means of closing appro-
priately selected ASDs. The fact that such a statement
can be made is a testament to the remarkable advances
made in the design and application of ASD closure
devices over the past 10 years. Improvements that cur-
rent devices incorporate include systems deliverable
through sheaths small enough for very small children,
materials increasingly resistant to fatigue, and self-cen-
tering characteristics that have reduced residual leaks
after device closure. The diversity of designs should
permit an increasing percentage of secundum defects to
be successfully closed.
We can anticipate continued refinement of ASD clo-
sure devices in the near future. Along with improve-
ments in technology, the field requires parallel
improvements in our ability to select patients appropri-
ate for device closure, minimizing the number who
undergo catheterization unnecessarily. The thoughtful
evaluation of these procedures demands carefully con-
structed prospective comparisons of catheter and surgi-
cal ASD closure. This is particularly true in light of
recent changes in the surgical approach to ASD clo-
sure. Such studies cannot be accomplished by a single
center and will be costly. Because they should not be
restricted to a single type of device, industry will not
support them. Thus such studies are likely to be con-
ducted only with governmental funding.
Jonathan J. Rome, MD
Philadelphia, Pennsylvania
R E F E R E N C E
1. King TD, Mills NL. Secundum atrial septal defect: nonoperative
closure during cardiac catheterization. JAMA 1976;235:2506-9.
12/1/102105
Online—www.aats.org
Now  you can get The Journal of Thoracic and Cardiovascular Surgery online. The Journal online brings you faster delivery time,
easy searching of current and back issues, links to PubMed, AATS, WTSA and other important sites, and more. Visit the Journal online
today.
